Background: Surgical enucleation is the treatment of choice for esophageal submucosal tumors (SMTs) with symptomatic, larger, or ill-defined lesions. The enucleation of SMTs has traditionally been performed via thoracotomy. However, minimally invasive approaches have recently been introduced and successfully applied. In this study, we present our experiences with the thoracotomic and thoracoscopic approaches to treating SMTs. Methods: We retrospectively reviewed 53 patients with SMTs who underwent surgical enucleation between August 1996 and July 2013. Demographic and clinical features, tumor-related factors, the surgical approach, and outcomes were analyzed. Results: There were 36 males (67.9%) and 17 females (32.1%); the mean age was 49.2±11.8 years (range, 16 to 79 years). Histology revealed leiomyoma in 51 patients, a gastrointestinal stromal tumor in one patient, and schwannoma in one patient. Eighteen patients (34.0%) were symptomatic. Fourteen patients underwent a planned thoracotomic enucleation. Of the 39 patients for whom a thoracoscopic approach was planned, six patients required conversion to thoracotomy because of overly small tumors or poor visualization in five patients and accidental mucosal injury in one patient. No mortality or major postoperative complications occurred. Compared to thoracotomy, the thoracoscopic approach had a slightly shorter operation time, but this difference was not statistically significant (120.0±45.6 minutes vs. 161.5±71.1 minutes, p=0.08). A significant difference was found in the length of the hospital stay (9.0±3.2 days vs. 16.5±5.4 days, p＜0.001). Conclusion: The thoracoscopic enucleation of submucosal esophageal tumors is safe and is associated with a shorter length of hospital stay compared to thoracotomic approaches.
INTRODUCTION
. Indications for thoracoscopic enucleation have not been established. Surgical therapy is usually indicated for patients with the presence of symptoms, a larger tumor size (＞3 cm), and the need to obtain a pathological diagnosis to exclude malignancy [4] .
Conventionally, the standard approach has been to perform enucleation through a thoracotomy. However, minimally invasive surgery using thoracoscopy and laparoscopy has recently been successfully applied and widely used. Few series of the thoracoscopic enucleation of esophageal SMTs have yet been reported, and therefore we investigated the results of the surgical enucleation of esophageal SMTs in our hospital and conducted a comparative analysis by dividing these cases into a thoracotomy group and a thoracoscopy group. The main indications for the surgical enucleation of esophageal SMTs were the presence of tumor-related symptoms, tumors greater than 3 cm, evidence of an increase in tumor size, and the need to obtain a pathologic diagnosis to exclude malignancy. The surgical approach was determined based on the location and size of the tumors. In most patients, a right-side approach was chosen, except for two patients in whom a left-side approach was used to treat tumors located at the esophagogastric junction. A double-lumen endotracheal tube was inserted into all patients, and all surgeries were performed with the patient in the lateral decubitus position.
METHODS

From
Since thoracoscopy was first introduced in our institution in 2006 for the enucleation of esophageal SMTs, it has been successfully applied and usually approached using four ports (two 5 mm ports and two 11 mm ports). After localization of the tumor, the mediastinal pleura were dissected, and a my- Median±standard deviation.
symptoms. Epigastric discomfort (n=5) was the most common symptom, followed by dysphagia (n=4), chest pain (n=4), dyspepsia (n=1), vomiting (n=1), and nonspecific gastrointestinal discomfort (n=3). The tumor was located in the upper thoracic esophagus in 18 patients, the middle thoracic esophagus in 21 patients, and the lower thoracic esophagus in 14 patients. The mean tumor size was 3.25±1.49 cm (range, 1 to 7 cm). The indications for surgical enucleation were a tumor greater than 3 cm or with increasing size in 17 patients, the presence of tumor-related symptoms in 18 patients, and the need to obtain a pathologic diagnosis in 17 patients.
In one patient, an incidentally detected SMT was enucleated during a planned operation for esophageal achalasia.
Surgeries were mainly performed through a right-side approach, with the exception of two patients with tumors located at the esophagogastric junction and deviating to the left side of the esophagus. A planned thoracotomy was performed in 14 patients, and a thoracoscopy was performed in 39 patients. After 2006, when thoracoscopy was introduced in our institution for the enucleation of esophageal SMTs, a thoracoscopic approach was initially used on all patients, except for one patient with a 5 cm tumor that had unclear boundaries with the adjacent azygos vein and the descending thoracic aorta. Intraoperative esophagoscopy was performed in seven patients. In five cases, intraoperative esophagoscopy was performed to confirm the mucosal integrity, and in two cases to identify the location of a small tumor. There was no mucosal damage in the five patients who underwent intraoperative esophagoscopy due to suspicion of mucosal tearing.
Mucosal injury occurred in only one patient, which was discovered in the course of thoracoscopic enucleation due to a large tumor (6 cm) with intensive adhesion to the mucosa. A primary repair was performed with conversion to a thoracotomy. Six patients (15.4%) required conversion to a thoracotomy during thoracoscopy. Of the six conversions, three were due to poor surgical visibility resulting from a pleural adhesion and a marked deviation of the esophagus to the left, two were due to difficulty in localizing very small tumors, and one was due to a mucosal injury, as mentioned above.
Histopathological examination identified 51 cases of leiomyoma, one case of a gastrointestinal stromal tumor, and one case of schwannoma. We determined that enucleation was sufficient treatment for the gastrointestinal stromal tumor because it was low-risk based on the mitotic index (less than five mitotic figures noted per 50 high-power fields), and there was no recurrence during a one-year follow-up period. There were no postoperative leakages or other major complications.
There was also no perioperative mortality. The mean length of the hospital stay was 10.9±5.1 days (range, 4 to 27 days).
The results of a comparative analysis evaluating the effect of the surgical approach are presented in (Fig. 1) .
The distribution of tumor size according to the surgical approach indicated that tumor size was not an inherent surgical limitation for thoracoscopic enucleation ( Jeon et al. [15] reported that esophagoscopy was performed during thoracoscopic enucleation in all of the 17 patients with benign esophageal SMTs that were included in their study, and suggested that intraoperative esophagoscopy may be helpful in identifying the location of a tumor and in determining a suitable direction for the esophageal access incision. In our study, intraoperative esophagoscopy was not routinely performed in all patients, but was performed in seven patients
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− 45 − for tumor localization and confirmation of mucosal integrity.
Intraoperative esophagoscopy could enhance the accuracy and safety of the thoracoscopic enucleation of esophageal SMTs, despite being a time-consuming procedure.
Our study has some relevant limitations. First, this was a retrospective analysis based on medical records over a relatively long period. Second, we mostly employed the thoracotomic approach in the early period included in the study, whereas thoracoscopic enucleation has been the preferred approach since 2006. Therefore, accumulated surgical experience might have affected the results of this study.
In conclusion, the thoracoscopic enucleation of esophageal SMTs is a safe and feasible approach and is associated with a shorter hospital stay. Technical difficulties that may occur in the thoracoscopic procedure can be addressed by intraoperative esophagoscopy. The thoracoscopic approach is recommended as the standard procedure to treat esophageal SMTs in experienced centers.
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